Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-20952

Motsko, S P; Russmann, S; Ming, E E; Singh, V P; Vendiola, R; Jones, J K (2009). Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. Pharmacoepidemiology and Drug Safety, 18(12):1214-1222.

[img] PDF - Registered users only
138kB
[img]Accepted Version
PDF - Registered users only
1MB

Abstract

PURPOSE: This study compared the effectiveness of rosuvastatin (RSV) to other statins prescribed in clinical practice in prevention of cardiovascular (CV) events. METHODS: This longitudinal inception cohort study, using Thomson Healthcare's MarketScan databases, included patients aged >/= 18 starting statin therapy during August 2003-December 2005. Patients were followed until 90 days after index statin monotherapy exposure, start of another lipid-lowering therapy, an event, end of eligibility, or end of study. The primary endpoint was a composite of CV death (in-hospital only), myocardial infarction, unstable angina, coronary revascularization, stroke, and carotid revascularization. Adjusted time-to-event analyses incorporating a propensity score covariate were used, and analyses were stratified by duration of statin exposure. RESULTS: Among 395 039 patients who met inclusion/exclusion criteria, 12% initiated RSV, and 9622 (2.4%) of the total patient population experienced an outcome event. The median duration of statin treatment and follow-up was 100 days and 180 days, respectively. No statistically significant difference in CV event rates between RSV and other statins was observed after adjustment for demographics and medical/prescription history (HR = 0.99, 95%CI = 0.93-1.06). However, with longer exposure time, there was a suggestion of increased benefit with RSV compared to other statins. CONCLUSIONS: The primary analysis showed similar incidence rates of CV-related events between the statin cohorts over a median of 180 days of follow-up.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
DDC:610 Medicine & health
Language:English
Date:December 2009
Deposited On:29 Sep 2009 15:40
Last Modified:27 Nov 2013 22:42
Publisher:Wiley-Blackwell
ISSN:1053-8569
Publisher DOI:10.1002/pds.1843
PubMed ID:19780020
Citations:Web of Science®. Times Cited: 4
Google Scholar™
Scopus®. Citation Count: 6

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page